|
|
|
|
|
Legal status
Patent not validated
| (51) | INT.CL. | A61K 31/4375 | |
| A61K 31/4184 | |||
| A61K 39/395 | |||
| A61K 39/00 | |||
| A61P 35/00 | |||
| A61K 45/06 |
| (11) | Number of the document | 3481393 |
| (13) | Kind of document | T |
| (96) | European patent application number | 17823723.6 |
| Date of filing the European patent application | 2017-06-14 | |
| (97) | Date of publication of the European application | 2019-05-15 |
| (45) | Date of publication and mention of the grant of the patent | 2021-04-14 |
| (46) | Date of publication of the claims translation |
| (86) | Number | PCT/IB2017/053521 |
| Date | 2017-06-14 |
| (87) | Number | WO 2018/007885 |
| Date | 2018-01-11 |
| (30) | Number | Date | Country code |
| PCT/CN2016/0885 | 2016-07-05 | WO |
| (72) |
SONG, Jing, CN
WANG, Lai, CN
LI, Kang, CN
ZHANG, Tong, CN
LUO, Lusong, CN
WEI, Min, CN
TANG, Zhiyu, CN
ZHANG, Guoliang, CN
ZHOU, Changyou, US
|
| (73) |
Beigene, Ltd.,
94 Solaris Avenue Camana Bay, Grand Cayman KY1-1108,
KY
|
| (54) | COMBINATION OF A PD-1 ANTAGONIST AND A RAF INHIBITOR FOR TREATING CANCER |
| COMBINATION OF A PD-1 ANTAGONIST AND A RAF INHIBITOR FOR TREATING CANCER |